Skip to main content
Fig. 8 | Journal of Experimental & Clinical Cancer Research

Fig. 8

From: Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis

Fig. 8

PYCR1 inhibition by pargyline enhances bortezomib sensitivity in vivo. A Treatment overview of 5TGM1 mice (n = 9/group). 5TGM1 mice were treated 5x/week with pargyline (100 mpk) and/or bortezomib 2x/week (0.6 mpk, starting 14 days after inoculation). All mice were sacrificed at day 30. B) Tumor burden was measured based upon eGFP positivity by flow cytometry (n = 9). eGFP positivity reflects the percentage of MM cells (= 5TGM1 vivo) present in the BM microenvironment. C-D Western blot analysis of protein synthesis-related proteins, originating from 5TGM1 vivo cells. Bar graphs represent the pixel intensity measured by Image Studio Lite v5.2. All graphs are shown relative to vehicle (n = 3 shown, n = 5 total). par = pargyline, bz = bortezomib, mpk = milligram per kilogram. Significance was determined by one-way ANOVA. * p ≤ 0.05, *** p ≤ 0.001 **** p ≤ 0.0001

Back to article page